Humoral Hypercalcemia of Malignancy Caused by Parathyroid Hormone-Related Protein-Secreting Medullary Thyroid Carcinoma: A Case Report
Open Access
- 1 January 2026
- journal article
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.25-0546
Abstract
INTRODUCTION: Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor arising from the parafollicular C cells, accounting for approximately 1.5% of all thyroid cancers. Although calcitonin secreted by the MTC typically lowers calcium levels, serum calcium concentrations usually remain within the normal range due to compensatory parathyroid hormone (PTH) secretion. Hypercalcemia of malignancy is broadly categorized as humoral hypercalcemia of malignancy (HHM), mediated by parathyroid hormone-related protein (PTHrP), or local osteolytic hypercalcemia. We report a rare case of HHM caused by a PTHrP-secreting MTC.CASE PRESENTATION: A 60-year-old woman visited our hospital with weight loss, fatigue, and a large right-sided neck mass. Laboratory tests revealed marked hypercalcemia (16.5 mg/dL), hypophosphatemia, and renal dysfunction. The intact PTH level was within the normal range, whereas the PTHrP level was elevated to 5.7 pmol/L, consistent with HHM. Tumor marker analysis revealed marked increases in carcinoembryonic antigen and calcitonin levels. Imaging studies revealed a large mass in the right thyroid lobe without evidence of regional or distant metastasis. Fine-needle aspiration confirmed the diagnosis of MTC. Genetic testing was negative for rearranged during transfection mutations and multiple endocrine neoplasia 2A, supporting a sporadic form. Hypercalcemia was managed with intravenous hydration (saline solution, 2 L/day for 10 days), elcatonin (80 units/day for 9 days), and a single dose of zoledronic acid. The patient underwent a right thyroid lobectomy. Histopathological analysis confirmed MTC without extra-thyroidal extension or lymph node metastasis (Union for International Cancer Control pT3aN0M0 stageII). Postoperatively, the serum PTHrP levels decreased to normal, and the patient recovered without complications. At the 8-month follow-up, no evidence of recurrence was observed.CONCLUSIONS: Herein, we present a rare case of MTC that caused hypercalcemia via PTHrP production. Although HHM is uncommon in thyroid cancer, the condition can cause severe hypercalcemia requiring prompt diagnosis and treatment. HHM should be considered in patients with thyroid cancer with hypercalcemia, and PTHrP measurement may aid in the diagnosis.Keywords
This publication has 11 references indexed in Scilit:
- SAT581 Parathyroid Hormone Related Protein-induced Hypercalcemia In Medullary Thyroid Carcinoma In Pediatric Patient With MEN2AJournal of the Endocrine Society, 2023
- Humoral Hypercalcemia of Malignancy with a Parathyroid Hormone-Related Peptide-Secreting Intrahepatic Cholangiocarcinoma Accompanied by a Gastric CancerCase Reports in Endocrinology, 2017
- Humoral Hypercalcemia in Uterine Cancers: A Case Report and Literature ReviewAmerican Journal of Case Reports, 2017
- Hypercalcemia of malignancy: An update on pathogenesis and managementNorth American Journal of Medical Sciences, 2015
- Anaplastic Thyroid Carcinoma with Humoral Hypercalcemia of Malignancy (HHM): An Autopsy Case ReportEndocrine Journal, 2004
- TRANSFORMATION TO UNDIFFERENTIATED FROM DIFFERENTIATED THYROID CANCER ASSOCIATED WITH REMARKABLE LEUKOCYTOSIS AND HYPERCALCEMIA-REPORT OF A CASE-Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2000
- Thyroid Anaplastic Carcinoma Producing Granulocyte-Colony-Stimulating Factor and Parathyroid Hormone-Related Protein.Internal Medicine, 1995
- CLINICAL STUDY OF THYROID CANCER WITH HYPERCALCEMIAThe journal of the Japanese Practical Surgeon Society, 1993
- Current Status of the ApudomasAnnals of Surgery, 1977
- Secretion of Parathyroid Hormone in Patients with Medullary Thyroid CarcinomaJournal of Clinical Investigation, 1974